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Background: Ticagrelor increases adenosine plasma levels and coronary blood flow in response to intravenous adenosine administration. 
It has been suggested that ticagrelor may influence endothelial function in patients with CAD. We aimed to assess the offset of ticagrelor’s 
effect on endothelial function.
methods: This is a prospective, observational study, in stable CAD patients with prior percutaneous coronary intervention (PCI) due to 
acute coronary syndrome (ACS), under ticagrelor maintenance dose (MD) 90mg x 2, who are about to discontinue it due to completion 
of 12 months of antiplatelet therapy. Endothelial function was assessed by Peripheral Arterial Tonometry (EndoPat 2000 system, 
Itamar Medical, Caesarea, Israel) at Day 0 (immediately after receiving the last pill of ticagrelor) and at Day 2 and Day 5 post ticagrelor 
discontinuation. Reactive Hyperemia Index (RHI) and Augmentation index (AI) are calculated by automated software. Endothelial 
dysfunction (ED) was defined as RHI<1.67.
results: We identified 24 eligible patients (95.8% men, 12.5% diabetics, 25% current smokers with a mean age of 63±12.3 years). All 
patients except for 1 were on aspirin 100mg daily. RHI and AI did not differ significantly between Day 0 and Day 2 [1.77(1.58-2.14) vs 
1.68(1.57-2.06), p=0.5 and 17.5(3.25-32.75) vs 21.0(11.3-30.5), p=0.1 respectively]. No difference in ED rate was observed between Day 
0 and Day 2 (37.5% vs 50.0%, p=0.5). RHI and AI did not differ significantly between Day 0 and Day 5 [1.77(1.58-2.14) vs 1.67(1.48-1.99), 
p=0.4 and 17.5(3.25-32.75) vs 24.5(14.5-31.0), p=0.1]. No difference in ED rate was observed between Day 0 and Day 5 (37.5% vs 41.7%, 
p=1.0 respectively).
Conclusion:  Discontinuation of ticagrelor MD does not significantly alter endothelial function in patients with stable CAD, as assessed with 
Peripheral Arterial Tonometry.
